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Abstract
Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most
patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited. We
explored the efficacy of a novel agent, HE3235, in inhibiting growth of CRPC in preclinical models. Castrated
male mice were implanted subcutaneously with LuCaP35V CaP xenografts in the presence and absence of
5′-androstenediol (AED) and treated with HE3235. To investigate the effect of HE3235 on CaP tumor in the bone,
castrated mice were injected intratibially with C4-2B CaP cells and treated with HE3235. Serum prostate-specific
antigen (PSA) levels, tumor volume, immunohistochemistry, gene expression, and levels of intratumoral androgens
were analyzed. HE3235 significantly prolonged the tumor doubling time of LuCaP35V, decreased androgen recep-
tor expression, and lowered levels of intratumoral testosterone by ∼89% and dihydrotestosterone by ∼63% in
both the presence and the absence of AED. HE3235 inhibited tumor growth in the bone environment. Weights
of tumored tibiae of HE3235-treated animals were lower than those of control (P = .031), and normalized PSA
levels were also significantly decreased at the end of study by HE3235 treatment (P = .0076). HE3235 inhibits
the growth of subcutaneous CRPC as well as CRPC in the bone environment. Our data show that HE3235 exhibits
a wide range of effects, including alteration of androgen receptor signaling and reductions in levels of intratumoral
androgens. Our results support ongoing clinical investigations into the effectiveness of HE3235 in the setting of
CRPC and warrants further studies into the mechanisms behind the effects of HE3235.
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Introduction
Current treatment of advanced prostate cancer (CaP) involves androgen
deprivation therapy, but unfortunately, most patients eventually prog-
ress to castration-resistant CaP (CRPC). The current criterion standard
treatment involves the use of docetaxel-based regimens. Although these
regimens offer an improvement in survival over previous therapies for
CRPC, the overall survival for these patients still remains only 18 to
20 months [1,2]. Thus, a great deal of emphasis is placed on the devel-
opment of new, more effective therapies for CRPC.
Although the mechanisms behind development of CRPC are not
fully understood, a central theme is that continued activity of the
androgen receptor (AR), despite castrate levels of circulating androgens,
is critical for tumor growth. There exists a plethora of literature focusing
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on the role of AR in CRPC: AR levels, AR transcriptional complexes,
AR mutations, and ligand-independent mechanisms of AR activation
(reviewed in [3–5]).
Initially, androgen deprivation therapy focuses on suppression of
testicular production of androgens, testosterone (T) and its metabolite,
dihydrotestosterone (DHT). The adrenal gland, however, represents an
additional source of androgens in humans (i.e., 5′-androstenediol
[AED], dehydroepiandrosterone). Adrenal androgens can directly acti-
vate AR or be converted to its cognate ligand DHT. Because the syn-
thesis of adrenal androgens is unaffected by treatment methods used
to decrease testicular androgen production (i.e., luteinizing hormone-
releasing hormone agonists), they are thought to be involved in the
growth of CRPC. In support of this hypothesis, secondary hormonal
therapies aimed at blocking production of adrenal androgens (i.e.,
ketoconazole) have resulted in prostate-specific antigen (PSA) declines
and delays in disease progression [6]. Further complicating the picture
surrounding continued activity of AR in CRPC are the results of recent
investigations showing significant levels of intratumoral Tand DHT in
patients with CRPC. We and others have reported on the continued
presence of intratumoral androgens in both xenograft models of CRPC
and in metastatic CaP patient samples despite castrate levels of cir-
culating testicular androgens [7,8]. In addition, CaP cells have recently
been shown to have de novo androgen synthesis capability through up-
regulation of enzymes involved in steroidogenesis [9]. These data, to-
gether with the marginal success of the available secondary hormonal
therapies [6], clearly demonstrate the critical need for development of
agents that will be more effective at the inhibition of AR signaling. Many
new inhibitors of AR signaling are being tested for their efficacy in treating
CRPC in preclinical and clinical settings along with several new drugs
aimed at blocking specific enzymes in the steroidogenesis pathway [10,11].
We have previously demonstrated that HE3235, a synthetic ana-
log of a naturally occurring androstenediol, inhibits AED-stimulated
growth of LNCaP cells in vitro and in vivo [12]. In the present study,
we have evaluated the effects of HE3235 in two models of CRPC:
LuCaP35V xenografts grown subcutaneously and C4-2B xenografts
grown in the bone environment. Our data show that treatment with
HE3235 inhibits the growth rate of subcutaneous CRPC tumors by
25% in animals stimulated with AED and by 43% in animals not
stimulated with AED. In addition, HE3235 inhibited the growth
of CRPC in the bone environment as demonstrated by a 17% reduc-
tion in tibiae weight along with an approximately 50% reduction in
normalized PSA levels. The effects of HE3235 include reductions in
AR expression, alterations in the AR signaling pathway, and decreases
in the levels of intratumoral androgens.
Material and Methods
Cell Lines
LuCaP35V, a CRPC subline of LuCaP 35 CaP xenograft, was
derived from the lymph node metastasis of a patient who had previ-
ously undergone an orchiectomy [13]. It is maintained by serial pas-
sage in castrated severe combined immunodeficient (SCID) male
mice. C4-2B, a CRPC subline of LNCaP cells (a gift from Dr. Chung,
Emory University), was derived from a bone metastasis [14], and is
maintained in vitro under standard tissue culture conditions.
Transient Transfection Reporter Assays
For transient transfection, C4-2B cells grown in RPMI 1640
(Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine
serum (Atlanta Biological, Atlanta, GA) under standard tissue culture
conditions and a single suspension of LuCaP35V cells prepared from
tumors [15] were used. Cells were transiently transfected with an an-
drogen response element (ARE) reporter (provided by Dr. Plymate,
University of Washington, Seattle, WA) or with a 5.8-kb PSA luciferase
plasmid (provided by Dr. Kim, Fred Hutchinson Cancer Research
Center, Seattle, WA) using the Amaxa Nucleofector with solution V
on program 27 as per the manufacturer’s instructions (Amaxa Bio-
systems, Inc, Gaithersburg, MD). The hTK renilla-luciferase plasmid
was transfected under the same conditions to allow for normalization
of transfection efficiencies. Control cells were mock-transfected. After
transfection, cells were placed in RPMI 1640with 5% charcoal-stripped
serum (Invitrogen) and treated with 0, 10, and 50 nM HE3235. Cells
were incubated for 48 hours, and luciferase activity was detected with a
Dual-Luciferase Reporter Assay (Promega, Madison,WI) using a Tecan
GENios Plus luminometer (Phenix Research Products, Hayward, CA).
Proliferation Study
C4-2B cells were plated in a six-well plate (200,000 cells per well)
in RPMI 1640 medium with 5% charcoal-stripped serum, and
HE3235 was added at 0, 10, and 50 nM concentrations. After three
days, viable cells were counted using the Trypan blue exclusion assay.
Experiments were performed in triplicate and repeated twice. Prolif-
eration studies with LuCaP35V were not possible as because this line
does not proliferate in vitro.
In Vivo Studies
All animal procedures were performed in compliance with the
University of Washington Institutional Animal Care and Use Com-
mittee and National Institutes of Health guidelines. For subcutane-
ous studies, 50 male CB-17 SCID mice (Charles River Laboratories,
Wilmington, MA) were castrated, and after a 2-week recovery period,
half of the mice then received subcutaneous AED pellets (5 mg, 60-day
time release; IRA, Sarasota, FL). The other half of animals received
placebo pellets. LuCaP35V was implanted subcutaneously (∼20 mg
tumor bits) 3 days after implantation of the pellets. Animals were ran-
domized into the following study groups when tumor volume exceeded
100 mm3: 1) Control LuCaP35V, group receiving a placebo pellet +
placebo treatment (HERF202), n = 12; 2) LuCaP35V + HE3235,
group receiving the placebo pellet + HE3235, n = 12; 3) AED-
LuCaP35V, group receiving the AED pellet + HERF202, n = 12;
and 4) AED-LuCaP35V + HE3235, group receiving the AED pellet +
HE3235, n = 11. HE3235, 17α-ethynyl-5α-androstan-3α, 17β-diol
(Hollis Eden Pharmaceuticals, Inc, San Diego, CA) was administered
through intraperitoneal (IP) injection once daily, 5 d/wk for 4 weeks
through IP injection at dose of 160 mg/kg. HE3235 was suspended
in Captisol (CyDex, Lenexa, KS) for IP injections to increase bio-
availibily. Placebo consisted of Captisol vehicle (HERF202). Tumor vol-
umes were measured twice weekly, and blood samples were drawn
weekly for PSA determinations (IMx Total PSA Assay; Abbott Labo-
ratories, Abbott Park, IL). Exponential growth equations were used
for calculations of tumor doubling times. Animals were killed after
4 weeks of treatment when tumors exceeded 1000 mm3 or if other-
wise compromised. Sacrifice PSA index was calculated by dividing the
serum PSA levels by the tumor volume. At sacrifice, half of each tumor
was processed for paraffin embedding and immunohistochemistry
(IHC), and the other half was flash frozen for gene expression analysis
and determinations of intratumoral androgen levels. Statistical analyses
of HE3235 effects were performed using Student’s t tests (Prism
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GraphPad; GraphPad Software, San Diego, CA). Results with differ-
ences yielding P ≤ .05 were considered significant.
For intratibial studies, 30 male CB-17 SCID mice were castrated,
and after 2 weeks of recovery, the intratibial injections were performed
as previously described [16]. Blood samples were drawn weekly for
determination of serum PSA levels, which was used to evaluate tumor
growth. When tumors were established in the bone (PSA >0.6 and
<5 ng/ml), animals were randomized into two study groups: 1) Control
C4-2B, group receiving HERF202, n = 9; and 2) C4-2B + HE3235,
group receiving HE3235 (160 mg/kg IP), n = 10. Animals were dosed
daily (IP injections as previously mentioned), 7 d/wk for 4 weeks. Ani-
mals were killed after 4 weeks or if otherwise compromised. Tibiae were
excised, weighed, decalcified in EDTA, and embedded in paraffin for
analyses. Effects of tumor growth and HE3235 treatment on bone was
examined using radiographs (Faxitron Specimen Radiography System,
Model MX-20; Faxitron x-ray Corporation, Wheeling, IL) and bone
mineral density (BMD) measurements (PIXImus Lunar densitometer;
GE Healthcare, Waukesha, WI), which were obtained before sacrifice.
Statistical analyses were performed using Student’s t tests (Prism Graph-
Pad; GraphPad Software). Results with differences yielding P ≤ .05 were
considered significant.
Determinations of Levels of Intratumoral Androgens
Four animals from each group with LuCaP35V tumors were used
for analyses of intratumoral androgens. Levels of intratumoral androgen
were determined by mass spectrometry as previously described [8].
Levels of intratumoral androgens were compared using Student’s t tests,
and results yielding P ≤ .05 were considered significant.
RNA Extraction
Tumor fragments (50-100 mg) were placed into 1 ml of STAT-60
solution (Tel-Test, Inc, Friendswood, TX) and homogenized using
Omni Tips (Omni International, Marietta, GA). The RNA extrac-
tion was carried out as recommended by the manufacturer’s protocol.
Gene Expression Profiling and Analysis from
Subcutaneous Tumors
For oligo array analyses, we used four pools of RNA from group 1
(control LuCaP35V) and four pools of RNA from group 2 (LuCaP35V +
HE3235). Each pool contained an equal amount of RNA from three
different tumors from the specific group. A reference standard RNA
for use in two-color oligo arrays was prepared as described previously
[15]. Total RNA was amplified using the Ambion MessageAmp aRNA
Kit (Ambion, Inc, Austin, TX). Amplified amino-allyl RNA from each
pooled sample was labeled with Cy3 fluorescent dye (reference amino-
allyl RNA was labeled with Cy5) and hybridized to 44K whole human
genome expression oligo microarray slides (Agilent Technologies, Inc,
Santa Clara, CA).
Fluorescence array images were collected (Agilent DNA oligo array
scanner G2565BA, Agilent Technologies, Inc), and Agilent Feature
Extraction software was used to grid, extract, and normalize the data.
Spots of poor quality or average intensity levels (<300) were removed
from further analysis. The Statistical Analysis of Microarray (SAM)
program (http://www-stat.stanford.edu/~tibs/SAM/) was used to ana-
lyze expression differences between treated and untreated specimens.
Unpaired, two-sample t tests were calculated for all probes passing filters
and controlled for multiple testing by estimation of q values using the
false discovery rate method. These results were then reduced to unique
genes by eliminating all but the highest scoring probe for each gene.
Gene set enrichment analysis of GO (http://www.geneontology.org/)
categories was performed using the EASE (http://david.abcc.ncifcrf.
gov/) software.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Real-time polymerase chain reaction (PCR) confirmation of se-
lected gene expression from the oligo array results was performed
as previously described [15]. The same pools of RNA were used as
for the oligo array analysis. See Table W1 for primers used to deter-
mine expression of genes of interest.
Immunohistochemistry
Five-micrometer sections of paraffin-embedded subcutaneous and
intratibial tumors were used. IHC was performed by standard pro-
cedure [17], using an anti–human AR mouse monoclonal antibody
(1:60 dilution; BioGenex, San Ramon, CA). For analysis, a quasi-
continuous score was created bymultiplying each nuclear intensity level
(1 indicates no stain; 2, faint stain; 3, intense stain) by the corresponding
overall percentage of cells at that intensity for the entire tumor, and then
totaling the results [18]. All evaluations were blinded, and statistical
analysis was performed using Student’s t tests. IHC for PSA expression
in intratibial tumors was done using an anti–human PSA rabbit poly-
clonal antibody (3 μg/ml; Dako, Carpinteria, CA).
Results
In Vitro Studies
Our previous studies with LNCaP cells demonstrated that while
HE3235 (Figure 1A) inhibits proliferation it stimulates AR-mediated
transcription [12]. In the present study, we used castration-resistant
C4-2B cells, which express the same mutated AR as LNCaP cells,
and LuCaP35V cells, which express wild-type AR. First, we deter-
mined if HE3235 alters AR-mediated transcription in these cells
using ARE- and PSA-promoter-reporter constructs. Our results show
that HE3235 increases AR-mediated transcription using both of the
reporter plasmids in C4-2B cells that express mutated AR. AR-
mediated transcription was also increased in LuCaP35V that express
wild-type AR, but this activation did not reach significance (Fig-
ure 1, B–E ). This might be due to a lower transfection efficiency
of these cells in vitro. There are differences in the magnitude of
the increases in AR-mediated transcription between the C4-2B and
LuCaP35V cells, and we hypothesize that they might be attributed to
the differences of HE3235 effects on mutated and wild-type AR. Im-
portant to the intratibial studies, our results also show that treatment
with HE3235 causes a significant decrease in the proliferation of C4-2B
cells in a dose-dependent fashion (ANOVA, P < .0001; Figure 1F ).
Effect of HE3235 on AED-Supplemented LuCaP35V
Subcutaneous Tumors
In the preclinical setting, we first evaluated effects of HE3235 on
LuCaP35V in the presence of AED. Castrated male mice were sup-
plemented with AED pellets to closer mimic the human adrenal
gland secreting AED because the adrenal gland in mice lacks the en-
zymes necessary for steroidogenesis [19]. Treatment with HE3235
significantly inhibited growth of LuCaP35V in mice supplemented
with AED; doubling time of AED-LuCaP35V + HE3235 was
13.15 ± 2.96 days (mean ± SD) in comparison to 9.87 ± 1.64 days
of AED-LuCaP35V (P = .007; Figure 2A). Treatment with HE3235
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also resulted in slight increases in serum PSA levels versus the control
AED-LuCaP35V animals, but these differences did not reach signifi-
cance. Similarly, the PSA index at the end of the study was also higher
in HE3235-treated animals, and this difference did not reach signifi-
cance (AED-LuCaP35V, 0.09 ± 0.04 ng/ml per cubic millimeter;
and AED-LuCaP35V + HE3235, 0.13 ± 0.09 ng/ml per cubic milli-
meter, P = .17). However, these elevations in PSA are in concordance
with the above in vitro studies demonstrating increases in AR-mediated
transcription by HE3235 treatment.
Effect of HE3235 on LuCaP35V Subcutaneous Tumors
Our previous data showed that HE3235 inhibits proliferation of
LNCaP cells in the presence and absence of AED in vitro [12].
Therefore, in this study, we set out to investigate whether HE3235
inhibits growth of CaP tumors in castrated male mice in the absence
of AED. These experimental conditions mimic the clinical scenario
of patients treated with agents aimed at blocking adrenal synthesis of
androgens (e.g., ketoconazole). In this setting, HE3235 significantly
inhibited the tumor doubling times of LuCaP35V (LuCaP35V +
HE3235, 18.2 ± 6.28 days; untreated LuCaP35V, 10.44 ± 1.8 days;
P < .0001; Figure 2B). HE3235 treatment resulted in significant in-
creases in serum PSA levels in the treated animals versus control animals
bearing LuCaP35V tumors in the period of 1 to 3 weeks after treat-
ment initiation (P < .0001; Figure 2B). PSA levels were not significantly
higher in the treated animals at the end of the study. We hypothesize
that this is due to the decreases in tumor volume. This explanation is
supported by results showing a significantly higher PSA index in the
LuCaP35V + HE3235 animals than PSA index in the LuCaP35V
animals, 0.18 ± 0.07 versus 0.07 ± 0.02 ng/ml per cubic millimeter,
respectively (P < .0001).
Effects of HE3235 on the Growth of CaP in Bone
To investigate the effect of HE3235 on CRPC tumors growing in
the bone environment, we used C4-2B cells directly injected into
Figure 1. Effects of HE3235 on C4-2B and LuCaP35V cells in vitro. (A) Chemical structure of HE3235 and AED. (B and C) HE3235 in-
creased AR-mediated transcription in C4-2B cells in vitro as demonstrated by ARE-luc and PSA-promoter-luc reporter assays. C4-2B cells
were transfected with ARE-luc (B) or PSA-promoter-luc (C) using Amaxa. After 2 days, the luciferase activity was measured. The luc
signal was normalized to renilla luciferase. The results are plotted as fold change over the untreated C4-2B cells. (D and E) Single-cell
suspensions of LuCaP 35V cells were prepared by dissociation of subcutaneous tumors. The cells were transfected with ARE-luc (D) or
PSA-promoter-luc (E) using Amaxa. Treatment with HE3235 increases AR-mediated transcription in LuCaP35V CaP cells. (F) HE3235
effect on AR-mediated transcription in C4-2B cells. C4-2B cells were grown under standard tissue culture conditions (see Materials
and Methods) and treated with HE3235. HE3235 significantly inhibited C4-2B proliferation. RLU indicates relative light units.
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murine bone. We selected C4-2B cells for these experiments because
they exhibit a mixed osteoblastic/osteolytic response when grown in
the bone environment similar to that seen in patients with CaP bone
metastases. Our results show that HE3235 treatment resulted in a
decreased weight of tumored tibiae in comparison to control tumored
tibiae (0.056 ± 0.004 vs 0.068 ± 0.015 g, P = .031; Figure 3A), suggest-
ing smaller tumor volume and/or lower amount of bone. The weight of
the HE3235-treated tumored tibiae was not significantly different from
that of the contralateral nontumored tibiae of the same animals. In con-
trast to the previously mentioned study with LuCaP35V, HE3235
treatment resulted in decreases of serum PSA in this model. When nor-
malized to enrollment, HE3235 initially increased serum PSA levels
(trend: P < .1), whereas at weeks 3 and 4, significant decreases were
detected (Figure 3A). Because the serum PSA levels were lower in ani-
mals with HE3235-treated C4-2B tumors versus animals with control
C4-2B tumors, we next examined the effects of HE3235 treatment on
the bone. Our results show that C4-2B cells decreased BMD of the
tibiae, and despite the lower tumor burden, no differences in BMD
were detected between HE3235-treated versus control C4-2B tumored
tibiae (0.05 ± 0.004 versus 0.049 ± 0.004 g/cm2, P = .65; Figure 3A).
Figure 2. Effects of HE3235 on LuCaP35V in vivo. (A) HE3235 inhibited growth of AED-supplemented LuCaP35V subcutaneous tumors
(25% inhibition, P = .007), whereas PSA levels were slightly but not significantly increased during the study. LuCaP35V tumors were
grown subcutaneously in AED-supplemented animals. When tumors reached 100 mm3, the animals were randomized between two
groups; control and HE3235-treated groups (HE3235: 160 kg/kg 5 d/wk). The doubling times were calculated for each individual tumor
using exponential growth curve for determinations of average doubling times (line represents average doubling time per group). Left
panel — control tumors, middle panel — HE3235-treated tumors, right panel — HE3235 treatment effects on serum PSA levels (values
are normalized to enrollment). (B) HE3235 inhibited growth of LuCaP35V subcutaneous tumors (43% inhibition, P < .0001), whereas
PSA levels were significantly increased at weeks 2 to 3 of the treatment. Left panel — control tumors, middle panel — HE3235-treated
tumors, right panel— serum PSA levels (values are normalized to enrollment). (C) Tumor volume at sacrifice was significantly decreased
by HE3235 treatment in castrated male animals with and without AED supplementation.
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Also, no differences in BMD were detected between normal contralat-
eral tibiae of the two groups (Figure 3A).
Representative radiographs and hematoxylin and eosin (H&E)
staining of the tumored tibiae are shown in Figure 3B. These images
show an osteoblastic reaction associated with growth of C4-2B tumors
in bone and tumor foci between newly formed woven bone in both
HE3235-treated and control tibiae (Figure 3B). We have also per-
formed IHC analysis of PSA expression. Our results show that
HE3235-treated tumor exhibited stronger PSA immunoreactivity de-
spite lower levels of serum PSA (Figure 3B).
Analysis of Intratumoral Androgens in LuCaP35V
Subcutaneous Tumors
We have previously shown that there are detectable levels of intra-
tumoral androgens in CRPC xenografts and in human CRPC samples
despite anorchid levels of circulating androgens [8]. Thus, we set out
to determine whether the HE3235 inhibitory effects involve alterations
in levels of intratumoral androgens. Treatment with HE3235 signifi-
cantly lowered levels of T and DHT in LuCaP35V tumors both in
the presence and in the absence of AED when compared with respec-
tive control animals (Table 1). Animals receiving HE3235 with AED
Figure 3. Effect of HE3235 on growth of C4-2B in bone. (A) C4-2B cells were injected into tibiae of castrated male mice and when tumors
were established half of the animals were treated with HE3235 (160 mg/kg) daily for 28 days. Left panel— HE3235 treatment resulted in
decreases in weight of tumored tibiae suggesting inhibition of tumor growth while not exhibiting any significant effects on nontumored
tibiae. Furthermore, HE3235-treated tumored tibiae weight was not significantly different as contralateral nontumored tibiae. Middle
panel — HE3235 treatment caused alterations in serum PSA levels, which were significantly decreased at weeks 3 and 4 of the treat-
ment (values are normalized to enrollment). *P< .001, #P< .10. Right panel— HE3235 treatment did not have any significant effects on
BMD of tumored and nontumored tibiae. BMD was measured at the site of tumor-cell injection adjacent to the growth place. (B) Rep-
resentative examples of H&E, PSA immunoreactivity, and radiographs of HE3235-treated and control tibiae are shown. Left panel— H&E
staining show tumor growth in the bone marrow cavity next to the growth plate (located on the right-hand side). Multiple tumor foci are
present between bone trabeculae secondary to the growth of this tumor in bone (magnification, ×10). Middle panel — HE3235-treated
tibiae show intensive PSA immunoreactivity (brown staining) in comparison to untreated tumored tibiae. Right panel — representative
radiographs of tibia from each group.
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supplementation had a 63% reduction in T levels in tumors versus
control AED-supplemented tumors (P < .001), and a 40% reduction
in DHT levels (P = .015). Interestingly, HE3235 caused even larger
reductions in levels of intratumoral androgens in tumors growing in
castrated animals not supplemented with AED. T levels were 93%
lower in LuCaP35V + HE3235 versus control LuCaP35V tumors (P =
.006), and DHT levels were reduced by 85% in HE3235-treated
LuCaP35V in comparison to control LuCaP35V tumors (P < .001).
Owing to the small size of intratibial tumors, we were unable to deter-
mine the intratumoral androgen levels in these specimens.
Gene Expression Analysis of LuCaP35V Subcutaneous Tumors
In an attempt to delineate in more detail the mechanisms of
HE3235 effects on CRPC, we set out to investigate alteration in
RNA expression levels in LuCaP35V tumors, which resulted from
HE3235 treatment. We performed gene expression analysis on con-
trol LuCaP35V and LuCaP35V + HE3235 groups because HE3235
proved most efficacious in this experimental setting. To compare the
overall expression patterns of control LuCaP35V and HE3235-
treated LuCaP35V tumors on oligo arrays, log2 ratio measurements
were analyzed using the SAM software to perform an unpaired two-
sample t test (http://www-stat.stanford.edu/_tibs/SAM/). A false dis-
covery rate of q values less than 5% was considered significant and set
the threshold for differential expression at greater than a 1.6-fold
change with treatment. At this level of significance, there were 355
unique genes upregulated and 30 unique genes downregulated in
HE3235-treated LuCaP35V versus control LuCaP35V. An EASE
gene set enrichment revealed significant changes in a multitude of
cellular pathways associated with various biologic processes. Owing
to our previous findings that HE3235 stimulates AR-mediated tran-
scription as determined by reporter assay [9], and our present results
demonstrating the effects of HE3235 on levels of intratumoral andro-
gens, we focused further investigations on alterations associated with
AR-mediated transcription and on enzymes involved in steroidogenesis.
Our results show that 67 of 355 HE3235-upregulated and 8 of 30
HE3235-downregulated messages have been previously reported to
be regulated by androgens (Table W2), whereas the analysis of expres-
sion levels of selected enzymes associated with the steroidogenesis path-
way (Table W3) did not reveal any significant changes fitting the
previously mentioned criteria. The oligo array analysis also showed that
AR messenger RNA (mRNA) levels were significantly decreased by
HE3235 treatment (−3.1-fold).
We used real-time PCR to validate some of the oligo array results.
We have elected two of the most downregulated genes, AR and AK5;
five highly upregulated AR-regulated genes with suggested roles in
CaP progression; and we also included PSA and hK2, two well-
known AR-regulated genes that did not show altered expression on
oligo arrays. Real-time PCR confirmed the oligo array analysis re-
sults showing significant down-regulation of AR and AK5 mRNA
in HE3235-treated tumors as well as the up-regulation of several
AR-regulated genes, although not all genes examined resulted in sta-
tistically significant changes. In animals supplemented with AED, we
observed a diminished and in some instances, an abolished effect on
gene expression in response to HE3235 (Figure 4). Despite the fact
that the oligo array analysis did not show any significant alteration in
expression of 13 enzymes associated with steroidogenesis, we examined
levels of three of these, HSD17B3, AKR1C3, and SRD5A1 by PCR.
Even this analysis did not reveal any significant alterations in mRNA
levels of these enzymes after HE3235 treatment (data not shown).
Effects of HE3235 on AR Immunoreactivity
The results of the oligo arrays and real-time PCR results showed that
levels of AR transcript were decreased by treatment with HE3235.
Therefore, the effects of HE3235 on levels of AR protein were inves-
tigated. IHC analysis showed significant decreases in the nuclear local-
ization of AR after HE3235 treatment; the AR score of LuCaP35V +
HE3235 was 248 ± 8 versus 198 ± 28 of control (P = .0048), whereas
alteration of the AR score in AED-LuCaP35V + HE3235 versus AED-
LuCaP35V did not reach significance (228 ± 36 vs 208 ± 8, P = .28;
Figure 5). The AR score of HE3235-treated C4-2B intratibial tumors
was also significantly lower versus control C4-2B tumors (236 ± 15 vs
182 ± 15, P < .001; Figure 5).
Discussion
We have recently reported that HE3235 inhibits growth of AED-
stimulated LNCaP cells in vitro and in vivo [12]. However, LNCaP
cells are androgen-sensitive and express a mutated AR. Despite the rel-
atively high frequency of mutations in AR reported in CRPC, which
can alter AR responses to various steroids, most CRPC tumors express
wild-type AR [20]. Therefore, to further support the clinical potential
of this compound, our first objective was to determine whether
HE3235 inhibits growth of CRPC LuCaP35V cells that express
wild-type AR. Our results clearly demonstrate that HE3235 inhibits
growth of CRPC cells that express wild-type AR and that HE3235 in-
hibits growth of LuCaP35V not only in the presence of AED but also
in the absence of AED. Interestingly, the inhibition was even more pro-
nounced when AED was absent. Although the mechanisms behind
these differences in tumor growth are not known at present, our results
indicate that in a clinical setting, HE3235 might have more beneficial
effects when used in men on secondary androgen ablation regimens
that include inhibitors of adrenal androgen synthesis. However, despite
the inhibition of growth, HE3235 did not eradicate the tumors, but
merely slowed down tumor growth. Further studies are needed to de-
termine if higher doses of HE3235 or more frequent administration
would result in the elimination of the tumors.
Serum PSA levels are used to monitor disease progression as well
as effectiveness of treatment. HE3235 treatment of animals bearing
LuCaP35V tumors resulted in increases of serum PSA and in PSA
index despite the inhibition of tumor growth. In concordance with
Table 1. Intratumoral Androgen Levels in LuCaP35V Subcutaneous Tumors.
Androgens AED-LuCaP35V AED-LuCaP35V + HE3235 Control LuCaP35V LuCaP35V + HE3235
T (pg/mg) 2.90 ± 0.31 1.06 ± 0.35 1.47 ± 0.67 0.10 ± 0.05
DHT (pg/mg) 3.03 ± 0.65 1.81 ± 0.31 4.28 ± 1.04 0.64 ± 0.17
Values are mean ± SD.
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these in vivo results, we also show that AR-mediated transcription
was increased by HE3235 in vitro using ARE- and PSA-promoter-
reporter assays, further supporting stimulation of AR-mediated tran-
scription despite growth inhibition. Because inhibition of tumor growth
along with increases in AR-mediated transcription is not well docu-
mented in the literature, we further evaluated this negative association
by oligo array analysis, which confirmed increases in AR-mediated tran-
scription based on higher levels of messages which expression is regu-
lated by AR. To further complicate the situation of decreased tumor
volume, increased serum PSA, and increased levels of multiple AR-
regulated genes, HE3235 treatment decreased the expression of the
AR mRNA and lowered levels of nuclear AR in the HE3235-treated
tumors.More detailed investigations of the effects of HE3235 on tumor
growth and AR-mediated transcription will be required to fully under-
stand this interplay regulation of tumor growth and AR signaling. How-
ever, we currently have two working hypotheses: 1) levels of HE3235
in the tumors are sufficient to cause increases in AR-mediated transcrip-
tion despite lower levels of AR and lower intratumoral androgens and
2) other mechanisms, independent of AR, are involved in stimulation
of expression of AR-regulated genes. For example, it has recently been
reported that mitogen-activated protein kinase pathway stimulates
ARE-reporter activity in PC-3 and DU 145 cells that lack AR [21].
One of the important recent findings in CaP research is that there
are measurable levels of intratumoral androgens in CRPC tumors de-
spite anorchid levels of serum androgens [8]. Abiraterone, a novel
inhibitor of steroidogenesis currently evaluated in preclinical and
clinical settings, reduces serum androgens in patients and may func-
tion by suppressing intratumoral androgens in CRPC [10,22].
Therefore, we examined whether the inhibition of tumor growth
by HE3235 is also associated with altered levels of intratumoral
Figure 4. Real-time PCR validation of the androgen-regulated genes that demonstrated response to treatment with HE3235 on oligo array
analysis. We confirmed AR down-regulation concomitantly with AR activation as demonstrated by differential changes in AR-regulated
genes. The addition of AED seems to attenuate the effect of HE3235 on these genes. ODC1 indicates ornithine decarboxylase 1;
GPR64, G protein–coupled receptor 64; ARG2, anterior gradient homolog 2 (Xenopus laevis); SAA2, serum amyloid A2; RUNX1, runt-related
transcription factor 1; hK2, human glandular kallikrein; AK5, adenylate kinase 5. Numbers in parentheses show fold change in oligo array
analysis. Significant differences were detected in number of mRNA in LuCaP35V treated with HE3235 versus control tumors. *P < .05.
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androgens. In both non-AED and AED-supplemented animals,
HE3235 treatment resulted in significant reductions in intratumoral
T and DHT. A greater suppression of intratumoral androgens was de-
tected in LuCaP35V + HE3235 tumors versus tumors grown in the
presence of AED. These differences might be instrumental in the less
pronounced inhibition of growth in AED-supplemented tumors. One
potential mechanism resulting in decreased levels of intratumoral an-
drogen might be HE3235 inhibition of the transcription of enzymes
involved in steroidogenesis because increased messages have been de-
tected in CRPC metastases [8]. However, despite decreased levels of
intratumoral androgens, HE3235 did not alter the transcription of se-
lected enzymes associated with steroidogenesis. Nonetheless, transcrip-
tional control does not represent the only means by which to control
intratumoral androgen production. HE3235 suppression of T and
DHT in all tumors may be the result of either a blockade on import
of androgenic precursors or inhibition of enzymatic activity of the
components of the steroid synthesis pathway. The exact mechanism be-
hind this suppression of intratumoral androgens is not known, and
delineation of the mechanism(s) will require further investigations on
HE3235’s effect on enzyme activity in vitro and on transporters of
androgens and their precursors (e.g., SLCO1B3 and SLCO2B1).
Even with dramatic reductions in the levels of intratumoral andro-
gens, LuCaP35V tumors were not eliminated. Their growth was
merely slowed. This may indicate either of the following: 1) the
low levels of intratumoral androgens still present in LuCaP35V +
HE3235 tumors are sufficient to drive CRPC tumor growth and
greater reductions in levels of intratumoral androgens will be neces-
sary for complete inhibition of growth; or 2) a subset of truly castration-
resistant tumor cells exist in these tumors that do not require androgens
for growth. Therefore, as new agents aimed at blocking the intracrine
synthesis of androgens become available, improvements in patient out-
comes must be tempered against howmuch suppression of intratumoral
androgen production is achieved, and drugs aimed at decreasing expres-
sion of AR as well as agents that will kill AR-negative cells need to be
developed and evaluated.
One of the most frequent sites of CaP metastases is bone [16]. It is
important that new pharmaceuticals aimed at treating advanced CaP
are tested against CaP growing within the bone environment. Our
results show that HE3235 inhibits the growth of CRPC in bone
as demonstrated by decreased tibiae weight as well as decreased serum
PSA levels in HE3235-treated animals. The decreases in serum PSA
levels are interesting. We have shown in vitro that HE3235 increases
AR-mediated transcription in both C4-2B and LuCaP35V cells using
reporter assay, and we show increased serum PSA levels in vivo with
subcutaneous LuCaP35V tumors treated with HE3235. However, se-
rum PSA levels in our intratibial studies were decreased by the HE3235
treatment. We hypothesize that because treated tumors are producing
more PSA, an even greater reduction in tumor volume is necessary be-
fore serum PSAvalues decrease in comparison to control tumors. Serum
PSA increases caused by HE3235 treatment of larger subcutaneous
tumors initially overshadows the concomitant inhibition of tumor
growth. In the intratibial study, treatment is started on considerably
smaller enrollment tumor volumes that are more susceptible to growth
inhibition. With smaller enrollment tumor volumes in the intratibial
study, the balance between HE3235 effects on AR-mediated transcrip-
tion and inhibition of tumor growth is reached sooner as is demon-
strated by the initial elevation of serum PSA levels in HE3235-treated
animals followed by lower levels thereafter. Our in vitro experiments,
demonstrating HE3235 inhibition of C4-2B proliferation taken to-
gether with our IHC analysis showing activity of HE3235 within the
bone environment, further support the premise that HE3235 inhibits
CRPC growth within the bone.
In conclusion, our results show that HE3235 inhibits growth of
CRPC in multiple models of CaP, including inhibition of CRPC in
the bone environment. It invokes a variety of cellular alterations con-
tributing to its ability to inhibit growth of CaP cells, including de-
creases in levels of AR messages and AR nuclear localization as well as
inhibition of the production of intratumoral androgens. Our results
warrant further investigation into mechanisms of HE3235 action
and clinical investigation of HE3235 in the treatment of CRPC.
Figure 5. Effects of HE3235 on AR immunoreactivity. Sections of treated and control tumors (AED-LuCaP35V and LuCaP35V subcu-
taneous tumors and C4-2B intratibial tumors) were stained with anti-AR antibody, and nuclear staining was quantified based on intensity
of immunoreactivity and percentage of positive nuclei. HE3235 significantly decreased the AR score in LuCaP 35V and C4-2B tumors,
although the decreases were not significant in AED-LuCaP35V. Original magnification: AED-LuCaP35V and LuCaP 35V, ×20; C4-2B, ×10.
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Table W1. Real-time PCR Primers.
17BHSD3 Hydroxysteroid (17-beta) dehydrogenase 3 5′: CTGAAGCTCAACACCAAGGTCA NM_000197
3′: CTGCTCCTCTGGTCCTCTTCAG
AR Androgen receptor 5′: GGACTTGTGCATGCGGTACTCA NM_000044
3′: CCTGGCTTCCGCAACTTACAC
AGR2 Anterior gradient homolog 2 (Xenopus laevis) 5′: GTCCCCAGGATTATGTTTGTTGACC NM_006408
3′: AGTCTTCTCACACTTCTTCTGGTTTC
AK5 Adenylate kinase 5 5′: GGAGGTGAAGCAAGGGGAAGAGTT NM_174858.1
3′: TCCTTTGGAGAAGGCGGTTGGTC
AKR1C3 Aldo-keto reductase family 1, member C3 5′: GAGAAGTAAAGCTTTGGAGGTCACA NM_003739
3′: CAACCTGCTCCTCATTATTGTATAA
GPR64 G protein–coupled receptor 64 5′: CCAAAGAAA ATGTCAGGAAGCAATGG NM_001079858.1
3′: AGCAGTGTGGTGGAGTTAGTGGAG
hK2 Human glandular kallikrein 2 5′: ATGTTGTGTGCTGGGCTCTGGAC NM_005551
3′: GGTTGGC TGCGATCCTGTCCTTG
ODC 1 Ornithine decarboxylase 1 5′: ATGTGGGTGATTGGATGCTCTTTGA NM_002539
3′: CAGGCTGCTCTGTGGCGTTTCAT
PSA Prostate-specific antigen 5′: CCCCAGAATCACCCGAGCAG NM_001648
3′: ACCAGAGGAGTTCTTGACCCCAAAA
SAA2 Serum amyloid A2 5′: TGCTCGGGGGAACTATGATGCTG NM_030754
3′: GTCGGAAGTGATTGGGGTCTCTG
SRD5A1 Steroid-5-alpha-reductase, alpha polypeptide 1 5′: CCTGTTGAATGCTTCATGACTTG NM_001047
3′: TAAGGCAAAGCAATGCCAGATG
RUNX1 Runt-related transcription factor 1 5′: CTCCCTGAACCACTCCACTGCCT NM_001001890
3′: GACCCACATTCTGCCTTCCTCATAA
Table W2. Changes in Androgen-Regulated Genes by HE3235.
Gene Symbol Gene Name Fold Change
Increased expression
SAA2 Serum amyloid A2 5.8
FER1L3 fer-1-like 3, myoferlin (C. elegans) 4.1
RUNX1 Runt-related transcription factor 1
(acute myeloid leukemia 1; aml1 oncogene)
3.9
GPR64 G protein–coupled receptor 64 3.0
LOX Lysyl oxidase 2.5
RIS1 Ras-induced senescence 1 2.5
PKNOX2 PBX/knotted 1 homeobox 2 2.3
RBM24 RNA binding motif protein 24 2.3
ABCG1 ATP-binding cassette, subfamily G (WHITE),
member 1
2.2
GDF15 Growth differentiation factor 15 2.2
ODC1 Ornithine decarboxylase 1 2.2
TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible
sequence expressed in)
2.2
ABCC4 ATP-binding cassette, subfamily C (CFTR/MRP),
member 4
2.1
CDH26 Cadherin-like 26 2.0
GDA Guanine deaminase 2.0
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 2.0
IL1R1 Interleukin 1 receptor, type I 2.0
FADS1 Fatty acid desaturase 1 2.0
PXDN Peroxidasin homolog (Drosophila) 2.0
ChGn Chondroitin beta1,4 N -acetylgalactosaminyltransferase 2.0
AZGP1 alpha-2-Glycoprotein 1, zinc 2.0
FABP5 Fatty acid binding protein 5 (psoriasis-associated) 1.9
S100A11 S100 calcium binding protein A11 (calgizzarin) 1.9
LOC114984 Hypothetical protein BC014089 1.9
MAF v-maf musculoaponeurotic fibrosarcoma
oncogene homolog (avian)
1.9
LGALS3 Lectin, galactoside-binding, soluble, 3 (galectin 3) 1.9
GPX3 Glutathione peroxidase 3 (plasma) 1.9
LOC645904 Similar to mitotic spindle assembly checkpoint
protein MAD1 (mitotic arrest deficient-like protein 1)
(MAD1-like 1) (mitotic checkpoint MAD1
protein-homolog) (HsMAD1) (hMAD1)
(Tax-binding protein 181)
1.9
SAT Spermidine/spermine N1-acetyltransferase 1.9
CASP10 Caspase 10, apoptosis-related cysteine peptidase 1.8
CRISP3 Cysteine-rich secretory protein 3 1.8
PPM1E Protein phosphatase 1E (PP2C domain containing) 1.8
CTBP1 C-terminal binding protein 1 1.8
C15orf48 Chromosome 15 open reading frame 48 1.8
PGC Progastricsin (pepsinogen C) 1.8
PVRL3 Poliovirus receptor-related 3 1.8
C21orf122 Chromosome 21 open reading frame 122 1.7
RPL36A Ribosomal protein L36a 1.7
SLC26A2 Solute carrier family 26 (sulfate transporter), member 2 1.7
NFKBIZ Nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, zeta
1.7
AGR2 Anterior gradient 2 homolog (Xenopus laevis) 1.7
MICAL1 Microtubule-associated monoxygenase,
calponin and LIM domain containing 1
1.7
LFNG Lunatic fringe homolog (Drosophila) 1.7
MRPL33 Mitochondrial ribosomal protein L33 1.7
AMPD3 Adenosine monophosphate deaminase (isoform E) 1.7
MGC33839 Hypothetical protein MGC33839 1.7
RPLP1 Ribosomal protein, large, P1 1.7
ZNF33A Zinc finger protein 33A 1.6
AMACR alpha-Methylacyl-CoA racemase 1.6
RPL21 Ribosomal protein L21 1.6
GRHL2 Grainyhead-like 2 (Drosophila) 1.6
SUMO2 SMT3 suppressor of mif two 3 homolog 2 (yeast) 1.6
RAB32 RAB32, member RAS oncogene family 1.6
C6orf166 Chromosome 6 open reading frame 166 1.6
MT1G Metallothionein 1G 1.6
GNE Glucosamine (UDP-N -acetyl)-2-epimerase/
N -acetylmannosamine kinase
1.6
POPDC3 Popeye domain containing 3 1.6
TIMP2 TIMP metallopeptidase inhibitor 2 1.6
CLDN8 Claudin 8 1.6
LIPG Lipase, endothelial 1.6
Table W2. (continued )
Gene Symbol Gene Name Fold Change
RFPL1 Ret finger protein-like 1 1.6
LONPL Peroxisomal LON protease like 1.6
ARHGEF10 Rho guanine nucleotide exchange factor
(GEF) 10
1.6
RHOBTB3 Rho-related BTB domain containing 3 1.6
C14orf78 Chromosome 14 open reading frame 78 1.6
SAA3 Serum amyloid A3 1.6
FER1L4 Fer-1-like 3, myoferlin (C. elegans) 1.6
Decreased expression
JUN v-jun sarcoma virus 17 oncogene homolog (avian) −1.6
IRX5 Iroquois homeobox protein 5 −1.6
SLC3A1 Solute carrier family 3 (cystine, dibasic and
neutral amino acid transporters, activator of
cystine, dibasic and neutral amino acid transport),
member 1
−1.7
TFPI Tissue factor pathway inhibitor (lipoprotein-associated
coagulation inhibitor)
−1.7
JAG1 Jagged 1 (Alagille syndrome) −1.9
CD44 CD44 antigen (Indian blood group) −2.0
AR Androgen receptor (dihydrotestosterone receptor;
testicular feminization; spinal and bulbar
muscular atrophy; Kennedy disease)
−3.1
AK5 Adenylate kinase 5 −3.7
Table W3. Steroidogenesis Enzymes.
Gene Symbol Gene Name
AKR1C1 Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1;
20-alpha (3-alpha)-hydroxysteroid dehydrogenase)
AKR1C3 Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid
dehydrogenase, type II)
CYP11A1 Cytochrome P450, family 11, subfamily A, polypeptide 1
CYP17A1 Cytochrome P450, family 17, subfamily A, polypeptide 1
FASN Fatty acid synthase
HSD17B1 Hydroxysteroid (17-beta) dehydrogenase 1
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2
HSD17B3 Hydroxysteroid (17-beta) dehydrogenase 3
HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4
HSD17B6 Hydroxysteroid (17-beta) dehydrogenase 6
SRD5A1 Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid
delta 4-dehydrogenase alpha 1)
UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide B15
UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17
